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Abstract
Background: Treatment of Hepatitis C in children has a better outcome than in adults, and for this reason the
treatment had different views. However, in pediatric age hepatitis C is seen to have an evolution towards
chronicity. Today is a normal option to treat chronic hepatitis C as early as possible according to certain criteria.
The aim of this study is to show the results of treatment with interferon and ribavirin and the follow-up of children
diagnosed with chronic hepatitis C in our service.
Patients and methods: This is a prospective study which has included children 3 up to 15 years old (13 boys and
4 girls) diagnosed with chronic hepatitis C. All patients underwent a certain protocol, including liver biopsy prior to
treatment. Treatment consisted in use for 48 weeks of INF a-2b, 3 MIU/m2 three times a week s/c and ribavirin 15
mg/kg orally divided bid. Two patients were treated with PEGINF a-2b with dose 1.5 mcg/kg once a week s/c and
ribavirin 15 mg/kg. After the treatment all patients have stayed under our control for an average period of 24
weeks.
Results: At the end of the treatment we detected a patient with HCV-RNA positive. End Treatment Viral Response
was 94%. Six months later we found three patients who showed relapse of disease. Sustained Viral Response was
approximately 83%
Conclusion: The combination therapy of interferon with Ribavirin in treatment of children with chronic hepatitis C
provides a higher SVR when treatment is initiated at the earliest stages of hepatic changes. Side effects of therapy
are insignificant in comparison with results obtained
Keywords: Chronic Hepatitis C = CHC, HCV = Hepatitis C Virus, SVR = Sustained Viral Response, ETVR = End Treat-
ment Viral Response
Background
The combined treatment of Interferon and ribavirin is
currently approved for treatment of chronic hepatitis C
in children. Today, Peg interferon is found more conve-
nient because of the weekly administration (once a week
versus three times per week of conventional INF) as a
result of its long plasmatic half-life which is provided by
covalently linking a polyethylene glycol moiety to the
INF. There are not many studies on the effect of PEG-
INF in children and adolescents [1] However they show
that the efficiency of treatment is better in forms with
minimal histopathological changes, with low levels of
viral load, and with genotype other than genotype 1
[2-4]. An international study has observed pharmacoki-
netics, efficacy and safety of PEG-INF-a-2b 60 μg/m2/
week combined with ribavirin 15 mg/kg/weight in 107
children. Another study is conducted in North America
where the relative efficacy of the combination of PEG-
INF a-2a and ribavirin (55 children) is compared with
PEG-INF-a-2a as monotherapy (59 children). Over time
and in parallel with the studies in adults, experience has
been gained in children with INF-a monotherapy [5-9],
the combined use of INF-a and ribavirin [10,11], PEG-
INF monotherapy [12] and finally the combination of
PEG-INF with ribavirin, which is approved by the US
Food and Drug Administration (FDA) in December
2008 for use in children over 3 years old.* Correspondence: vdurro@moh.gov.al3Hospital Planning Directory, Ministry of Health, Bulevardi “ Bajram Curri”, no
1, Tirana, Albania
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The aim of our study is to show the results of treat-
ment with interferon and ribavirin and the follow-up of
children diagnosed with chronic hepatitis C in our ser-
vice. These patients have received multitransfusions as a
part of their therapy during treatment of their primary
illness. The prevalence of HCV is blood donor popula-
tion in Albania is 0.7% [13].
Patients and methods
Since November 2007 until March 2010, in our service
of Pediatric Gastrohepatology, we have treated 17 chil-
dren diagnosed with CHC. Diagnosis of these children is
performed through the Anti-HCV confirmed later with
HCV-RNA. We haven’t had any case of HCV associated
with hepatitis B, D, HIV or other pathology which
would severely damage liver function. The most part of
the patients, 14 of them came from the service of Onco-
hematology where they were treated for their illnesses.
All these children were in full remission of their basic
disease or were considered cured and had at least 12
months without treatment with cytostatics or immuno-
suppressive agents. All the patients who came from
oncohematology service have received multi-transfu-
sions. The age of the children was from 3 to 15 years
old. We had 13 boys and 4 girls. Two cases showed
hepatitis C with unknown transmission route and a
child is diagnosed with Gaucher disease treated with
replacement enzyme-therapy. We didn’t find any patient
with vertical transmission of the disease.
Method
Treatment which was carried out according to a proto-
col where is combined the use of interferon a2b (2 chil-
dren were treated with PEG-INF-a-2b) and ribavirin,
with a dose of 3MIU/m2 s/c three times a week for
INF-a-2b and 1.5mcg/kg s/c once a week for PEG-INF-
a-2b. The dosage of ribavirin has been 15 mg/kg/d
divided bid. A protocol was composed to follow up
patients during the treatment as shown in Table 1.
Ethical approval
This study is carried out in compliance with the Hel-
sinki Declaration known by Albanian Committee on
Bioethics (Rr. Reshit Petrela No 27, Tirana-Albania).
The parents of all children included in this study pro-
vided their consent
Results
Out of 17 children, 14 were first treated in pediatric ser-
vice of oncohematology with blood transfusions or its
by-products. This fact explain the main reason of HCV
transmission thorough transfusion. Two other children
had an unknown transmission of hepatitis C and a
patient with Gaucher disease. To each patient was per-
formed liver biopsy prior to treatment as show in Tables
1 and 2. Other biochemical data (liver tests, aminotran-
ferases, PT, protein electrophoresis etc.) are not pre-
sented in the summary table because the most part of
patients have had at the beginning of therapy normal
values of aminotransferases or slightly increased (1-2
times) without hyperbilirubinemia.
All our patients have had a moderate number of
copies of HCV RNA (only one patient with over 2 mil-
lion copies per ml). The prevalent histopathological pat-
tern is chronic hepatitis with minimal or moderate
lesions, but there isn’t any case with cirrhosis (F4) or
septal fibrosis (F3). The most frequent hematological
side effects were leucopenia which has been moderated
by allowing us to continue treatment. Another side
effect, not very rare, was fever and headache which were
present at the beginning of the treatment (Table 2). At
the end of treatment, only one patient was detected
with HCV RNA positive. End Treatment Viral Response
(ETVR)1 was 94%. Six months after the treatment we
found only three patients with HCV RNA positive. Sus-
tained Viral Response(SVR)2 was approximately 83%
Discussion
Chronic hepatitis C in children and teens is usually
silent (hepatitis c is known as “silent killer”) [14]. Hysto-
pathological changes in most of cases are minimal
showing mild degrees of inflammation and fibrotic
changes. A liver biopsy is recommended before begin-
ning the treatment. Some serious studies performed in
children with chronic hepatitis C in most of cases have
shown few histological lesions and the evaluation by
Table 1 The protocol of children during one year of treatment
Before beginning the
treatment
total blood count, liver function test, GGT(gamma glutamyl transferase), albumine, protein electrophoresis, total protein,
protrombine time, HCV RNA *, genotype, liver biopsy
After 1month total blood count, liver function test, protrombine time, GGT, albumine, total protein, protein electrophoresis,
sedimentation rate
After 3 months as the first month plus HCV RNA
After 6 months as the third month
After 9 months as the first month
* Due to the high cost HCV RNA and genotype was not performed under this Protocol. HCV RNA is accomplished before and at the end of the treatment and
approximately 6 months after treatment to assess SVR. Genotype is carried out for only three patients, who resulted 1b
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Table 2 Summary Chart of patients
Patients Age Sex Diagnosis HCV-RNA Liver Biopsy Treatment Side effects HCV-RNA Genotype
1 11 y M Non-Hodgking lymphoma 1.5 × 106 copies /ml Metavir**A1F1 INFa2b***Ribavirin Leucopenia Not detected
2 5 y M Non-Hodgking lymphoma 1.8 × 106 copies /ml Metavir A2F2 INFa2b***Ribavirin None Detected 1B
3 5 y M Testicular teratocarcinoma 761,000 copies/ml Metavir A2F0 INFa2b***Ribavirin None Not detected
4 6 y F Meduloblastoma 6.3 × 104 copies/ml Metavir A1F2 INFa2b***Ribavirin Leucopenia headache Not detected
5 12 y M Testicular seminoma 9.2 × 104 copies/ml Metavir A2F1 INFa2b***Ribavirin Fever Not detected
6 11 Y M Leukemia 3,600 copies/ml Metavir A1F1 INFa2b***Ribavirin None Not detected
7 10 y F Non-Hodgkin lymphoma 1.1 × 106 copies /ml Metavir A3F2 INFa2b***Ribavirin None Not detected 1B
8 6 y F Leukemia 1.8 × 106 copies /ml Metavir A2F1 INFa2b***Ribavirin None Not detected
9 3 y M Hemolytic anemia 1.5 x106 copies /ml Metavir A1F2 INFa2b***Ribavirin None Not detected
10 8 y M Gaucher 6.8 × 105 copies/ml Metavir A2F1 INFa2b***Ribavirin None Not detected
11 8 y M Leukemia 1.6 × 106 copies /ml Metavir A2F1 INFa2b***Ribavirin Myalgia Not detected 1B
12 11 y M Unknown 1.8 × 106 copies /ml Metavir A1F2 INFa2b***Ribavirin Headache Not detected
13 10 y M Leukemia 56,700 copies /ml Metavir A2F2 INFa2b***Ribavirin Fever Not detected
14 15 y F Faringeal Ewing -sarcoma 9.3 × 105copie/ ml Metavir A1F0 PEGINFa2b *** Ribavirin None Not detected
15 10 y M Leukemia 1.8 × 106 copies /ml Metavir A2F1 INFa2b***Ribavirin None Not detected
16 10 y M Unknown 1.5 x106 copies /ml Metavir A2F1 INFa2b***Ribavirin None Not detected
17 8 Y M Infantile fibrosis 2.5 x106 copies /ml Metavir A2F2 PEGINFa2b *** Ribavirin Fever, Cramps, Vomiting Not detected
*HCV-RNA are shown at the beginning and at the end of treatment. At the end we had only one patient with positive HCV RNA. ETVR = 94%. To each patient is performed an other HCV RNA of control (6 months
after treatment to determine SVR) which has resulted positive for three patients. SVR was approximately 83%
** METAVIR is a histopathological score which expresses the rank of inflammation (A) and hepatic fibrosis (F) in cases of hepatitis C, etc.. Missing -A0, A1-minimum, A2-moderate; A3-severe; F0-no fibrosis; F1-portal
fibrosis non-septal l; F2-portal fibrosis with few septal fibrosis; F3- septal fibrosis without cirrhosis, F4-cirrhosis














biopsy has been controversy, but still today remains the
only method to evaluate the severe cases [15-17] Only
1.3% (one in 80 children) can achieve to cirrhosis
[18,19]. Theoretically cirrhosis could be developed after
a mean time of 28 years [20,21]. The progress of fibrosis
is depended on the duration of infection when we don’t
have other risk factors that damage liver function. Some
other authors did not associate hepatic injury with the
duration of infection [22].
It have to be noted that we cannot predict the age
when this pathology can be more aggressive. Neverthe-
less children should spend a few decades being ill, until
the risk of resistance to treatment appears. A careful
treatment of patients with chronic infection, early in
their life is preferable to prevent the progression of the
disease [23-27]. In our study we achieved a SVR
approximately 83%, while in other serious studies they
reached values around 53% SVR for genotype 1, 93% for
genotype 2 and 3 and 80% for genotype 4. The relative
high result can be explained as below mentioned:
First of all, we were unable to define genotype for all
patients, but other studies conducted in our country
from Public Health Institute(unpublished data), indicate
that genotype 1 is more frequently. For this reason it
was decided to extend treatment up to 48 weeks.
It is thought that if we had predominantly “mild” gen-
otype except G1 means that a higher SVR is expected.
Secondly, we note that in our cases viral load was rela-
tively low. Today is known as “baseline” level of viral
load ≤600,000 UI/ml or 2,000,000 copies/ml [28]. We
had only one patient with over 2,000,000 copies/ml
(Table 2), which means a higher SVR.
Thirdly, the high result achieved can be explained
from minimal histopathology changes encountered in 17
patients. According to the METAVIR evaluation we
have not had any patient in F3 level (septal fibrosis with
few septa) or F4 (cirrhosis).
Above all, in our study, the use of INF combined with
ribavirin has been very well tolerable by all patients.
Among the most frequent side effects were fever, head-
ache, etc. known as “flu like symptoms”. Hematological
side effect was dominated by a moderate leucopenia so
we weren’t constrained to interrupt the treatment. We
hadn’t any child with anemia induced by ribavirin, so
we administrated a full dose in all patients. We were
unable to bring out an accurate conclusion about the
impact of INF on the impairment of growth velocity,
because we had a limited number of children involved
in this study. Today there are serious studies that assess
the growth of children during the treatment with INF
and 5 years later without treatment [29,30].
During the treatment we didn’t observe changes in
school performance or psychological disorders. We
hadn’t any child with thyroid dysfunction [31,32].
Finally, the combined therapy of INF with Ribavirin in
children and adolescents with chronic hepatitis C, in the
earliest stage and with low viral load, is associated with
higher SVR. Our data have also shown a very good tol-
erance of this combined therapy in pediatric ages. The
beginning of treatment is preferable before the period of
adolescence.
Endnotes
1“End Treatment Viral Response” is defined as undetect-
able serum HCV RNA in the end of treatment
2“Sustained Viral Response” is defined as undetectable
serum HCV RNA 6 months after treatment
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